A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 1,901–2,000 of 3,965
Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard
Wells, A. U. (2015) · European Respiratory Journal · doi:10.1183/09031936.00043915 · Cited by 14
Nishioka, Y., Homma, S., Ogura, T., Sato, S., Arai, N., Tomii, K., Kamio, K., Sakamoto, S., Miyazaki, Y., Tomioka, H., et al. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.04.008 · Cited by 12
Hsia, I., Asmani, M., & Zhao, R. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115194 · Cited by 12
Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis
Zhao, T., & Su, Y. (2025) · Journal of Respiratory Biology and Translational Medicine · doi:10.70322/jrbtm.2025.10001 · Cited by 29
The PERK/ATF4 pathway is required for metabolic reprogramming and progressive lung fibrosis
Pandey, J., Larson‐Casey, J. L., Patil, M. H., He, C., Pinthong, N., & Carter, A. B. (2025) · JCI Insight · doi:10.1172/jci.insight.189330 · Cited by 18
Associations of interstitial lung disease subtype and CT pattern with lung function and survival
Kim, J. S., Pugashetti, J. V., Ma, S., Huang, Y., Podolanczuk, A. J., Lynch, D. A., Oh, A. S., Mychaleckyj, J. C., Manichaikul, A. W., Rich, S. S., et al. (2025) · Thorax · doi:10.1136/thorax-2024-222149 · Cited by 24
Tong, Y., Sun, J. L., Jiang, X., Xu, J., Jia, Y. X., Wang, H., Wu, J., Li, Z., Sun, H., & Yang, G. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04743-2 · Cited by 16
Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough
Molyneaux, P. L., Moğulkoç, N., Günen, H., Doboszyńska, A., Kreuter, M., Neustifter, B., Mathur, V. S., Cassella, J. V., CORAL Study Group, Bremner, P. R., et al. (2026) · JAMA · doi:10.1001/jama.2025.26179 · Cited by 12
Adams, C. J., Shapera, S., Ryerson, C. J., Assayag, D., Johannson, K. A., Fell, C. D., Morisset, J., Manganas, H., Kolb, M. R. J., Hambly, N., et al. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106722 · Cited by 11
Ning, W., Xu, X., Zhou, S., Wu, X., Wu, H., Zhang, Y., Han, J., & Wang, J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.998662 · Cited by 15
Klee, S., Picart‐Armada, S., Wenger, K., Birk, G., Quast, K., Veyel, D., Rist, W., Violet, C., Luippold, A. H., Haslinger, C., et al. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00253.2021 · Cited by 13
The effects of lipoic acid on respiratory diseases
Guo, X., Wu, S., Shang, J., Dong, W., Li, Y., Peng, Q., Xie, Z., & Chen, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109713 · Cited by 15
Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis
Tomioka, H., Iwabayashi, M., Yokota, M., Hashimoto, R., & Amimoto, H. (2023) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2023.102213 · Cited by 15
Çilli, A., Öcal, N., Üzer, F., Çoşkun, F., Sevinç, C., Ursavaş, A., Yildiz, P., Deniz, P. P., Demirci, N. Y., Ozbey, G., et al. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.04.007 · Cited by 13
Kizawa, R., Araya, J., & Fujita, Y. (2023) · Inflammation and Regeneration · doi:10.1186/s41232-023-00295-1 · Cited by 15
Imperatorin ameliorates pulmonary fibrosis via GDF15 expression
Tsai, C., Chen, Y.-C., Li, Y., Wu, C.-T., Chang, P.-C., & Yeh, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1292137 · Cited by 11
Vitamin E stabilizes iron and mitochondrial metabolism in pulmonary fibrosis
Chang, J., Wang, J., Luo, B., Li, W., Xiong, Z., Du, C., Wang, X., Wang, Y., Tian, J., Li, S., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1240829 · Cited by 12
Lettieri, S., Bertuccio, F. R., Frate, L. D., Perrotta, F., Corsico, A. G., & Stella, G. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010547 · Cited by 17
“Similarly, the number of patients showing a significant (>50 mt) decline in 6MWT distance from baseline to week 52 was 27.5% lower in pirfenidone than placebo [123].”
BackgroundInfluentialZhao, H., Wang, R., Song, C., Liu, J., Chen, R., Zheng, M., Liu, W. L., Jiang, G., & Mao, W. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02942-w · Cited by 14
Interstitial Lung Disease Associated with Systemic Sclerosis
Mismetti, V., Si-Mohamed, S. A., & Cottin, V. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1786698 · Cited by 19
Lee, C. T., Hao, W., Burg, C., Best, J. H., Kolenic, G. E., & Strek, M. E. (2024) · Respiratory Research · doi:10.1186/s12931-024-02883-2 · Cited by 17
Choe, J., Hwang, H. J., Lee, S. M., Yoon, J., Kim, N., & Seo, J. B. (2024) · Investigative Radiology · doi:10.1097/rli.0000000000001103 · Cited by 16
Therapeutic approaches and novel antifibrotic agents in renal fibrosis: A comprehensive review
Lahane, G. P., Dhar, A., & Bhat, A. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23795 · Cited by 14
Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?
Bączek, K., & Piotrowski, W. J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1445923 · Cited by 12
Luppi, F., Manfredi, A., Faverio, P., Franco, G., Salvarani, C., Bendstrup, E. M., & Sebastiani, M. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103668 · Cited by 17
Emerging roles of noncoding RNAs in idiopathic pulmonary fibrosis
Wang, H., Sun, K., Peng, H. F., Wang, Y., & Zhang, L. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02170-5 · Cited by 17
Lee, S., Kim, J.-H., Song, Y., Kim, S., Kang, H. J., Kim, J., Lee, Y., & Seo, H. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07522-2 · Cited by 13
Baratella, E., Borghesi, A., Calandriello, L., Cortese, G., Casa, G. D., Giraudo, C., Grassedonio, E., Larici, A. R., Palmucci, S., Romei, C., et al. (2025) · La radiologia medica · doi:10.1007/s11547-025-01985-1 · Cited by 13
Proteomic Biomarkers of Survival in Non–Idiopathic Pulmonary Fibrosis Interstitial Lung Disease
Alqalyoobi, S., Smith, J. A., Maddali, M. V., Pugashetti, J. V., Newton, C. A., Kim, J. S., Linderholm, A., Chen, C., Ma, S., Bose, S., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202407-1506oc · Cited by 20
Provenzani, A., Vinci, D. L., Alaimo, M., Maria, S. D., Tuzzolino, F., Floridia, G., Stefano, R. D., Carollo, A., Callari, A., Polidori, P., et al. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986251341645 · Cited by 17
What if we made stratified medicine work for patients?
Britten, N., Pope, C. J., Halford, S., & Richeldi, L. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00499-3 · Cited by 13
Pirfenidone: Clinical trials and clinical practice in patients with idiopathic pulmonary fibrosis
Bando, M. (2016) · Respiratory Investigation · doi:10.1016/j.resinv.2016.03.007 · Cited by 12
“The ASCEND trial [14] was conducted in nine countries including the U.”
BackgroundMethodInfluentialPharmacogenetics and interstitial lung disease
Oldham, J. M., Noth, I., & Martínez, F. J. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000289 · Cited by 12
Idiopatic pulmonary fibrosis: A new paradigm
Avdeev, S. N. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh2017891112-122 · Cited by 13
Efficacies of rosiglitazone and retinoin on bleomycin-induced pulmonary fibrosis in rats
Yu, W., Mi, L., & Long, T. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4555 · Cited by 13
Guo, J., Hardie, W. D., Cleveland, Z. I., Davidson, C. R., Xu, X., Madala, S. K., & Woods, J. C. (2019) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00993.2018 · Cited by 12
Understanding Progressive Fibrosing Interstitial Lung Disease through Therapeutic Trials
Goldberg, H. J. (2019) · New England Journal of Medicine · doi:10.1056/nejme1911794 · Cited by 11
Refining the unilateral ureteral obstruction mouse model: No sham, no shame
Atkinson, J. M., Boden, T., Mocho, J.-P., et al. (2020) · Laboratory Animals · doi:10.1177/0023677220909401 · Cited by 12
Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?
Hadda, V., & Guleria, R. (2020) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_90_20 · Cited by 16
Pintado‐Berninches, L., Montes‐Worboys, A., Manguán-García, C., Arias‐Salgado, E. G., Serrano, A., Fernández-Varas, B., Guerrero, R., Iarriccio, L., Planas‐Cerezales, L., Güenechea, G., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202001160rr · Cited by 13
Choe, J., Kwon, B. S., Do, K., Hwang, H. S., Song, J. W., & Chae, E. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-95728-7 · Cited by 11
Deng, L., Chen, Y., Hu, X., Zhou, J., & Zhang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708463 · Cited by 13
“It was approved for the treatment of idiopathic pulmonary fibrosis (IPF) by the US Food and Drug Administration in 2014 (18).”
BackgroundAn Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis
Mateos‐Toledo, H., Mejía, M. E., Rodríguez-Barreto, Ó., Mejía-Hurtado, J. G., Rojas‐Serrano, J., Estrada, A., Castillo-Pedroza, J., Castillo-Castillo, K., Gaxiola, M., Buendía-Roldán, I., et al. (2020) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2019.08.008 · Cited by 12
Keow, J. Y., Cecchini, M. J., Jayawardena, N., Zompatori, M., JOSEPH, M. G., & Mura, M. (2022) · Respiratory Research · doi:10.1186/s12931-022-02067-w · Cited by 17
Fang, Q., Liu, S., Cui, J., Zhao, R., Han, Q., Hou, P., Li, Y., Lv, J., Zhang, X., Luo, Q., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.920766 · Cited by 15
“PFD had finished the phase three trial, represented a good effect on patients with IPF, but often comes along with gastrointestinal (GI) adverse events (AE), which may be brought by the oral administration (King et al., 2014; Lancaster et al., 2017).”
BackgroundNagy, T., Tóth, N. M., Palmer, E., Polivka, L., Csoma, B., Nagy, A., Eszes, N., Vincze, K., Bárczi, E., Bohács, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092129 · Cited by 15
Ebrahimpour, A., Ahir, M., Wang, M., Jegga, A. G., Bonnen, M., Eissa, N. T., Montesi, S. B., Raghu, G., & Ghebre, Y. T. (2022) · Scientific Reports · doi:10.1038/s41598-022-24985-x · Cited by 15
Predictors of pulmonary sequelae after COVID-19 pneumonia: A 12-month follow-up study
Bernardinello, N., Cocconcelli, E., Giraudo, C., Daverio, M., Castelli, G., Petrarulo, S., Bovo, M., Fichera, G., Cavinato, S., Cattelan, A. M., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1084002 · Cited by 13
Fu, C., Chen, L., Cheng, Y., Yang, W., Zhu, H., Wu, X., & Cai, B. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1114601 · Cited by 15
“Anti-fibrotic drugs (Pirfenidone and Nintedanib) have been approved to treat IPF, but they only slow the decline in lung function in IPF patients and do not improve survival (King et al., 2014; Richeldi et al., 2014).”
BackgroundLee, J. M., Kim, K., & Jo, Y. S. (2023) · Respiratory Medicine · doi:10.1016/j.rmed.2023.107242 · Cited by 14
Self-management interventions for people with pulmonary fibrosis: a scoping review
Lee, J. Y. T., Tikellis, G., Dowman, L., Jones, A. W., Hoffman, M., Mellerick, C., Malaguti, C., Khor, Y. H., & Holland, A. E. (2023) · European Respiratory Review · doi:10.1183/16000617.0092-2023 · Cited by 13
Determination and pharmacokinetic study of pirfenidone in rat plasma by UPLC–MS/MS
Sun, W., Jiang, Z., Zhou, L., Chen, R.-M., Wang, Z., Li, W.-S., Jiang, S.-M., Hu, G., & Chen, R. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.12.027 · Cited by 12
Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects
Bargagli, E., Bonti, V., Ferrari, K., Rosi, E., Bindi, A., Bartolucci, M., Moroni, C., & Voltolini, L. (2017) · In Vivo · doi:10.21873/invivo.11130 · Cited by 13
Sakamoto, K., Ito, S., Hashimoto, N., & Hasegawa, Y. (2017) · BMC Cancer · doi:10.1186/s12885-017-3521-0 · Cited by 12
Pedraza-Serrano, F., Jiménez‐García, R., López‐de‐Andrés, A., Hernández‐Barrera, V., Esteban‐Hernández, J., Sánchez-Muñoz, G., Puente‐Maestu, L., & de Miguel‐Díez, J. (2018) · Respiratory Medicine · doi:10.1016/j.rmed.2018.04.005 · Cited by 14
Vartiainen, V. A., Raula, J., Bimbo, L. M., Viinamäki, J., Backman, J. T., Ugur, N., Kauppinen, E. I., Sutinen, E., Joensuu, E. I., Koli, K. M., et al. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.04.019 · Cited by 15
“In phase 3 clinical trials, over 90% of the patients reported at least one adverse effect (18, 37).”
BackgroundNew treatment paradigms for connective tissue disease-associated interstitial lung disease
Kouranos, V., Miranda, G., Corte, T. J., & Renzoni, E. A. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000508 · Cited by 12
Scleroderma-related interstitial lung disease: principles of management
Das, A., Kumar, A., Arrossi, A. V., Ghosh, S., & Highland, K. B. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1575732 · Cited by 12
Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies
Kaner, R. J., Bajwa, E. K., El-Amine, M., Gorina, E., Gupta, R., Lazarus, H. M., Luckhardt, T., Mouded, M., Posada, K., Richeldi, L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201903-0592pp · Cited by 14
Self-citationPterostilbene alleviates pulmonary fibrosis by regulating ASIC2
Peng, Y., Zhang, Y., Zhang, Y., Wang, X., Xia, Y., Ye, T., Wu, Z., & Ke, H. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00474-7 · Cited by 13
Iwanami, Y., Ebihara, K., Nakao, K., Sato, N., Miyagi, M., Nakamura, Y., Sakamoto, S., Kishi, K., Homma, S. A., & Ebihara, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185336 · Cited by 15
Pulmonary Abscess as a Complication of Transbronchial Lung Cryobiopsy
Skalski, J. H., Kern, R. M., Midthun, D. E., et al. (2015) · Journal of Bronchology & Interventional Pulmonology · doi:10.1097/lbr.0000000000000182 · Cited by 12
Lung Disease in Rheumatic Disorders
Kelly, C. A. (2019) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.30.3.147 · Cited by 14
Ikeda, S., Sekine, A., Baba, T., Kato, T., Katano, T., Tabata, E., Shintani, R., Yamakawa, H., Oda, T., Okuda, R., et al. (2022) · Medicine · doi:10.1097/md.0000000000029232 · Cited by 11
Wu, X., Gou, H., Zhou, O., Qiu, H., Liu, H., Fu, Z., & Chen, L. (2022) · Respiratory Research · doi:10.1186/s12931-022-02192-6 · Cited by 11
From Epithelium to Therapy: Transitional Cells in Lung Fibrosis
Shin, S. Y., Chen, J., Krentsis, I. M., Reisner, Y., Abrencillo, R., Hussain, R., Wu, D., & Karmouty‐Quintana, H. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0372tr · Cited by 20
Grafanaki, K., Maniatis, A., Sotiropoulou, V., Pasmatzi, E., & Τzouvelekis, Α. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178394 · Cited by 16
“Emerging evidence suggests that fibroinflammatory remodeling is perpetuated by a self-sustaining loop involving persistent low-grade inflammation (inflammaging) in both aged skin and repeatedly injured tissue [16,92,95].”
Konishi, S., Arita, M., Ito, I., Tachibana, H., Takaiwa, T., Fukuda, Y., Watanabe, N., Tsubouchi, K., Masuda, G., Tanaka, M., et al. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.4118 · Cited by 12
Liu, H., Pang, Q., Cao, F., Liu, Z., Wei, W., Li, Z., Long, Q., & Jiao, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.921209 · Cited by 15
Chubachi, S., Okamori, S., Yamada, Y., Yamada, M., Yokoyama, Y., Niijima, Y., Kamata, H., Ishii, M., Fukunaga, K., & Jinzaki, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-24157-x · Cited by 11
Yang, F., Du, W., Tang, Z., Wei, Y., & Dong, J. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00730-y · Cited by 12
Qiu, S., Fu, X., Shi, Y., Zang, H., Zhao, Y., Qin, Z., Lin, G., & Zhao, X. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00111 · Cited by 12
Rautajoki, T., Lehto, J. T., Sutinen, E., Bergman, P., Sintonen, H., Rajala, K., Mäkelä, K., Hollmén, M., Saarto, T. H., & Myllärniemi, M. (2023) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0548 · Cited by 13
Sevilla, J. P. H., Memon, A., & Hinchcliff, M. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03090-y · Cited by 13
Shuvaev, S., Knipe, R. S., Drummond, M., Rotile, N. J., Ay, İ., Weigand‐Whittier, J., Ma, H., Zhou, I. Y., Roberts, J. D., Black, K., et al. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01845-2 · Cited by 11
No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis
Hoffman, T. W., van Moorsel, C. H. M., van der Vis, J. J., Biesma, D. H., & Grutters, J. C. (2023) · ERJ Open Research · doi:10.1183/23120541.00131-2023 · Cited by 14
Sofia, C., Comes, A., Sgalla, G., & Richeldi, L. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2281416 · Cited by 11
Okamoto, M., Fujimoto, K., Johkoh, T., Kawaguchi, A., Mukae, H., Sakamoto, N., Ogura, T., Ikeda, S., Kondoh, Y., Yamano, Y., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-49180-4 · Cited by 16
Advances in lung transplantation: 60 years on
Paraskeva, M. A., & Snell, G. I. (2024) · Respirology · doi:10.1111/resp.14721 · Cited by 18
“118,119 Given their impact on fibroblast proliferation there is growing interest in whether these drugs could impact the development of OB associated with BOS and the parenchymal and interstitial fibrosis associated with RAS.”
BackgroundZhu, X., Cao, M., Li, K., Chan, Y.-T., Chan, H. F., Mak, Y. W., Yao, H., Sun, J., Ong, M. T., Ho, K. K., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.05.028 · Cited by 26
“Most patients have to take oral PFD daily for more than 18 months, and the side effects include nausea, photosensitivity and gastrointestinal issues [44,45].”
BackgroundGhanem, M., Archer, G., Crestani, B., & Mailleux, A. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108669 · Cited by 14
Wang, T., Xu, L., Li, P., Zhang, C.-H., Zhang, C.-H., Wang, X., Xiang, L., Xu, Z.-P., & Shen, T. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155797 · Cited by 13
Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review
Han, M., Liu, Q., Ji, Z., Jin, L., Jin, W., & Gao, Z. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1411279 · Cited by 14
Patient-centered care in pulmonary fibrosis: access, anticipate, and act
Hofman, D. E., Magrì, T., Moor, C. C., Richeldi, L., Wijsenbeek, M. S., & Waseda, Y. (2024) · Respiratory Research · doi:10.1186/s12931-024-02997-7 · Cited by 15
Ouji-Sageshima, N., Hiyama, A., Kumamoto, M., Kitabatake, M., Hara, A., Furukawa, R., Hontsu, S., Kawaguchi, T., Sawabata, N., Muro, S., et al. (2024) · Cells · doi:10.3390/cells13242050 · Cited by 14
Li, Y., Xu, F., Fang, Y., Cui, Y., Zhu, Z., Wu, Y., Tong, Y., Hu, J., Zhu, L., & Shen, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1530797 · Cited by 13
Cheng, M., Jiao, Z., Lei, J., Li, M., Yang, K., Qi, S., Yu, X., Wang, Y., Yan, L., & Yu, G. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c03033 · Cited by 14
Li, R., Tai, Y., Zhang, X., Liu, Z., Si, H., Kong, D., Zhao, L., Li, J., & Midgley, A. C. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202500101 · Cited by 15
Kondoh, Y., Fujii, T., Inoue, Y., & Atsumi, T. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103900 · Cited by 14
Semren, N., Habel, N., Fernandez, I. E., Königshoff, M., Eickelberg, O., Stöger, T., & Meiners, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136188 · Cited by 14
Novel approaches to pulmonary fibrosis
Jenkins, G. R., & Goodwin, A. T. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-6-s45 · Cited by 11
Hashisako, M., Fukuoka, J., & Smith, M. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-44284-8.00008-9 · Cited by 12
Brooks, D. L. P., Zimmer, A. S., Wakefield, L. M., Lyle, L. T., Difilippantonio, S., Tucci, F. C., Illiano, S., Annunziata, C. M., & Steeg, P. S. (2018) · Oncotarget · doi:10.18632/oncotarget.25231 · Cited by 14
Eaden, J. A., Barber, C., Renshaw, S. A., Chaudhuri, N., & Bianchi, S. M. (2020) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v37i2.8587 · Cited by 12
Assessment and Management of Occupational Hypersensitivity Pneumonitis
Ojanguren, Í., Ferraro, V., Morisset, J., Muñoz, X., Fink, J. N., & Cruz, M. J. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.09.002 · Cited by 12
Okano, T., Kobayashi, T., Yasuma, T., D’Alessandro‐Gabazza, C. N., Toda, M., Fujimoto, H., Nakahara, H., Okano, Y., Takeshita, A., Nishihama, K., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.593620 · Cited by 12
Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis
LANCASTER, L. H., Fieuw, A. M., Meulemans, J., Ford, P., & Nathan, S. D. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106227 · Cited by 11
Self-citationSatsuma, Y., Ikesue, H., Kusuda, K., Maeda, M., Muroi, N., Mori, R., Kogo, M., Hirabayashi, R., Nagata, K., Nakagawa, A., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.529654 · Cited by 12
Kelly, B. T., Thao, V., Dempsey, T. M., Sangaralingham, L. R., Payne, S. R., Teague, T., Moua, T., Shah, N. D., & LIMPER, A. H. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01607-2 · Cited by 12
Bernardinello, N., Grisostomi, G., Cocconcelli, E., Castelli, G., Petrarulo, S., Biondini, D., Saetta, M. P., Spagnolo, P., & Balestro, E. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106686 · Cited by 16
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.